Partial encapsulation of stents
Abstract
A method of making an implantable medical device includes extruding a first ePTFE tube and a second ePTFE tube, cutting a plurality of slits in the first ePTFE tube, positioning a radially expandable support layer between the first and second ePTFE tubes so that the slits span portions of the support layer, and laminating the first ePTFE tube to the second ePTFE tube through openings in the support layer.

Term
Term ended
Expired 2 February 2020, 6.6 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
6 claims: 4 independent, 2 dependent
- 1A method for making a partially encapsulated radially expandable reinforce vascular graft (10), comprising providing a first expanded polytetrafluoroethylene layer of material (20), providing a second expanded polytetrafluoroethylene layer of material (40, 42, 50, 60, 70), disposing a radially expandable support layer consisting of at least one stent (30) over the first expanded polytetrafluoroethylene layer, placing the second expanded polytetrafluoroethylene layer (40, 42, 50, 60, 70) over the radially expandable support layer (30), and laminating the second expanded polytetrafluoroethylene layer (40, 42, 50, 60, 70) to the first expanded polytetrafluoroethylene layer, characterized by cutting a plurality of apertures (44, 52, 62, 72) into one of the expanded polytetrafluoroethylene layers (20, 40, 42, 50, 60, 70) and positioning the apertures (44, 52, 62, 72) with respect to the support layer, leaving portions of the support layer exposed through the apertures.
- 4A method for making a partially encapsulated radially expandable reinforced vascular :graft, comprising providing a first expanded polytetrafluoroethylene layer of material (20) providing a second expanded polytetrafluoroethylene layer of material (40), disposing a radially expandable support layer comprising at least one stent (30) over the first expanded polytetrafluoroethylene layer (20), placing the second expanded polytetrafluoroethylene layer (40, 42, 50, 60, 70) over the radially expandable support layer (30) and laminating the second expanded polytetrafluoroethylene layer (40, 42, 50, 60, 70) to the first expanded polytetrafluoroethylene layer (20), characterized by cutting a plurality of slits (52, 62, 72) into at least one of the tubular expanded polytetrafluoroethylene layers (50, 60, 70) before being positioned as part of the radially expendable reinforced vascular graft and positioning the slits (52, 62, 72) to span portions of the radially expandable support layer.
Independent claims4
23 paragraphs in 3 sections, as filed
1.
Field of the Invention
0001The present invention relates generally to the field of medical devices, and more particularly, to encapsulation of stents.
2.
Description of Related Art
0002Stents and related endoluminal devices are currently used by medical practitioners to treat portions of the vascular system that become so narrowed that blood flow is restricted. Stents are tubular structures, usually of metal, which are radially expandable to hold a narrowed blood vessel in an open configuration. Such narrowing (stenosis) occurs, for example, as a result of the disease process known as arteriosclerosis. Angioplasty of a coronary artery to correct arteriosclerosis may stimulate excess tissue proliferation which then blocks (restenosis) the newly reopened vessel. While stents are most often used to "prop open" blood vessels, they. can also be used to reinforce collapsed or narrowed tubular structures in the respiratory system, the reproductive system, biliary ducts or any other tubular body structure. However, stents are generally mesh-like so that endothelial and other cells can grow through the openings resulting in restenosis of the vessel.
0003Polytetrafluoroethylene (PTFE) has proven unusually advantageous as a material from which to fabricate blood vessel grafts or prostheses used to replace damaged or diseased vessels. This is partially because PTFE is extremely biocompatible causing little or no immunogenic reaction when placed within the human body. This is also because in its preferred form, <i>expanded</i> PTFE (ePTFE), the material is light and porous and is potentially colonized by living cells becoming a permanent part of the body. The process of making ePTFE of vascular graft grade is well known to one of ordinary skill in the art. Suffice it to say that the critical step in this process is the <i>expansion</i> of PTFE into ePTFE following extrusion from a paste of crystalline PTFE particles. Expansion represents a controlled longitudinal stretching in which the PTFE is stretched up to several hundred percent of its original length. During the expansion process fibrils of PTFE are drawn out of aggregated PTFE particle (nodes), thereby creating a porous structure.
0004If stents could be enclosed in ePTFE, cellular infiltration could be limited, hopefully preventing or limiting restenosis. Early attempts to produce a stent enshrouded with ePTFE focused around use of adhesives or physical attachment such as suturing (see for example <patcit id="pcit0001" dnum="US5405377A"><text>U.S. Patent No. 5,405,377 to Cragg</text></patcit>). However, such methods are far from ideal, and suturing, in particular, is very labor intensive. More recently, methods have been developed for encapsulating a stent between two tubular ePTFE members whereby the ePTFE of one-member contacts and bonds to the ePTFE of the other member through the openings in the stent. These methods are disclosed in recent publications <patcit id="pcit0002" dnum="WO9838947A"><text>WO 98/38947</text></patcit> and <patcit id="pcit0003" dnum="WO9628115A"><text>WO 96/28115</text></patcit>. However, such a monolithically encapsulated stent tends to be rather inflexible. In particular, radial expansion of the stent may stress and tear the ePTFE. There is a continuing need for a stent that is encapsulated to prevent cellular intrusion and to provide a smooth inner surface blood flow and yet still capable of expansion without tearing or delaminating and is relatively more flexible.
SUMMARY OF THE INVENTION
0005The present invention is directed in one aspect to a method in accordance with claim 1 and in another aspect to a method in accordance with claim 4.
0006It is an object of this invention to provide a method for making a stent device that has improved flexibility, yet maintains its shape upon expansion.
0007It is also an object of this invention to provide a method for making a stent encapsulated to prevent cellular infiltration wherein portions of the stent can move during radial expansion without stressing or tearing the encapsulating material.
0008These and additional objects are accomplished by an encapsulation process that leaves portions of the stent free to move during expansion without damaging the ePTFE covering. The most basic form of this invention is produced by placing a stent over an inner ePTFE member (e.g., supported on a mandrel) and then covering the outer surface of the stent with an outer ePTFE tube into which slits have been cut. The outer ePTFE tube is then laminated to the inner ePTFE through openings in the stent structure to capture the stent. By selecting the size and location of the slits it is possible to leave critical parts of the stent unencapsulated to facilitate flexibility and expansion. Not only does the slit prevent capture of the underlying PTFE, it forms a focal point for the PTFE to flex. A more complex form of the process is to place over the stent an ePTFE sleeve into which apertures have been cut. This "lacey" outer sleeve leaves portions of the stent exposed for increased flexibility and for movement of the stent portions during expansion without damaging the ePTFE. Although a single stent can be used, these approaches lend themselves to use of a plurality of individual ring stents spaced apart along an inner ePTFE tube and covered by a "lacey" ePTFE sleeve.
0009In the present invention, individual ring stents are partially encapsulated using the procedure outlined above. Preferably, ring stents of zigzag sinusoidal structure are placed "in phase" (e.g., peaks and valleys of one stent aligned with those of a neighboring stent) on the surface of a tubular ePTFE graft supported by a mandrel. A sleeve of ePTFE is cut using CO<sub>2</sub> laser so that openings are created, resulting in a "lacey" pattern. This "lacey" sleeve is then placed over the ring stents. The resulting structure is then subjected to heat and pressure so that regions of ePTFE become laminated or fused together where the lacey sleeve contacts the tubular graft. In addition, the ends of the stent can be completely encapsulated, by known methods, to stabilize the overall structure.
0010A more complete understanding of the encapsulation process will be afforded to those skilled in the art, as well as a realization of additional advantages and objects thereof, by a consideration of the following detailed description of the preferred embodiment. Reference will be made to the appended sheets of drawings which will first be described briefly.
BRIEF DESCRIPTION OF THE DRAWINGS
0011<ul id="ul0001" list-style="none" compact="compact"><li><figref idref="f0001">Fig. 1</figref> is a perspective view of a tubular ePTFE member with individual ring stents arranged thereon.</li><li><figref idref="f0001">Fig. 2</figref> is a perspective view of the "lacey" sleeve of the present invention.</li><li><figref idref="f0001">Fig. 3</figref> is a perspective view of the sleeve in <figref idref="f0001">Fig. 2</figref> placed over the structure of <figref idref="f0001">Fig. 1</figref>.</li><li><figref idref="f0002">Fig. 4</figref> is a perspective view of one configuration of the slitted sleeve of the present invention with longitudinally oriented slits.</li><li><figref idref="f0002">Fig. 5</figref> is a perspective view of a second configuration of the slitted sleeve of the present invention with circumferentially oriented slits.</li><li><figref idref="f0002">Fig. 6</figref> is a perspective view of a third configuration of the slitted sleeve as it is placed over the structure in <figref idref="f0001">Fig. 1</figref>.</li></ul>
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
0012The present invention satisfies the need for an encapsulated stent device to prevent restenosis that is flexible upon expansion and contraction so that the general structural form is retained. This is accomplished encapsulating a stent or a plurality of stent rings using an ePTFE covering into which openings have been cut.
0013Referring now to the drawings, in which like reference numbers represent similar or identical structures throughout, <figref idref="f0001">Fig. 1</figref> illustrates an initial step in constructing the partially encapsulated stent of the present invention. A tubular ePTFE graft <b>20</b> is placed over a mandrel for the assembly of a device <b>10</b> (<figref idref="f0001">Fig. 3</figref>). A stent is then placed over the graft <b>20</b>. In a preferred embodiment, as shown in <figref idref="f0001">Fig. 1</figref>, a series of zigzag sinusoidal ring stents <b>30</b> are placed over the outer surface of the graft <b>20</b>. Alternatively, one or more stents wherein each stent comprises more than one ring or hoop (e.g., where the rings are helically connected) can be used. The ring stents <b>30</b> can be made of any material but a preferred material is metal. The zigzag ring stents <b>30</b> may be assembled "in phase" with each adjacent ring stent having peaks and valleys aligned. Alternatively, the individual stents 30 can be "out of phase" to different degrees. It will be apparent that the phase relation of adjacent stents <b>30</b> will alter the lateral flexibility as well as the longitudinal compressibility of the structure. The phase relationship can be varied along the length of the device <b>10</b>, thereby altering the physical properties in different portions of the device <b>10</b>. Having individual ring stents <b>30</b>, as opposed to a single tubular stent, provides the advantage that the periodicity, or the number and precise shape of the zigzags per ring, can readily be varied along the length of the graft to influence flexibility and stability properties of the structure. Also, spacing of the individual stents (number of stents per unit length) as well as the phase relationship of stent to stent can be varied to produce stent grafts with desired properties. By placing the ring stents <b>30</b> over the outer surface of the tubular ePTFE graft <b>20</b>, the resulting structure has an inner (luminal) surface that is completely smooth to facilitate the flow of blood. However, there may be instances where the ring stents <b>30</b> or other tubular stents are advantageously placed in contact with the inner graft surface or on both the inner and outer surfaces, as one of ordinary skill in the art will readily appreciate.
0014<figref idref="f0001">Fig. 2</figref> shows the structure of a "lacey" graft <b>40</b> comprising a sleeve of ePTFE <b>42</b> into which apertures have been cut. This "lacey" graft <b>40</b> is placed over the ring stents <b>30</b> in the preferred embodiment. The "lacey" graft <b>40</b> is created by cutting openings <b>44</b> in a tubular ePTFE sleeve <b>42</b>. The openings <b>44</b> were cut into the sleeve by a CO<sub>2</sub> laser, although any other cutting technology could readily be employed. The "lacey" graft <b>40</b> is slid over the ring stents <b>30</b> and the underlying tubular graft <b>20</b> to form the preferred device <b>10</b> shown in <figref idref="f0001">Fig. 3</figref>. The device <b>10</b> is then exposed to heat and pressure, such as that caused by wrapping with PTFE tape followed by heating in an oven, thereby causing the ePTFE regions of the "lacey" graft <b>40</b> to fuse or laminate to the tubular graft <b>20</b> wherever they touch each other. It should be appreciated that the circumferential sections of ePTFE <b>46</b> that are placed over the ring stents <b>30</b> can encompass many different designs. As illustrated, a sleeve <b>42</b> with openings <b>44</b> cut out is one way of accomplishing the goal of flexibility and stability. The openings <b>44</b> between the circumferential sections of ePTFE <b>46</b> can be altered to control the degree of flexibility and stability desired. In the preferred embodiment shown in <figref idref="f0001">Fig. 3</figref>, the "lacey" graft <b>40</b> forms a number of circumferential sections <b>46</b>, which are intended to cover a portion of the circumference of each ring stent <b>30</b>, leaving the ends of the zigzags uncovered. By circumferentially covering only a portion of each ring stent <b>30</b>, the maximum amount of lateral flexibility is provided.
0015However, circumferentially covering the individual ring stents <b>30</b> without any longitudinal support would result in a structure with little longitudinal strength and stability that would be prone to "telescoping". Thus, the longitudinal sections <b>48</b> that connect the circumferential sections of ePTFE <b>46</b> are important, because the longitudinal sections <b>48</b> are completely laminated to the underlying graft <b>20</b> and act as "anti-compression" devices by resisting the shortening of the structure <b>10</b> (the double thickness of ePTFE resists telescoping of the longitudinal sections <b>48</b>). The width of the circumferential sections <b>46</b> and the longitudinal sections <b>48</b> control longitudinal strength and stability versus lateral flexibility. By adjusting these parameters, grafts can be made more or less flexible with greater or lesser anti-compression strength. In the preferred embodiment, four longitudinal sections <b>48</b> are formed and the ends of the structure <b>10</b> are completely encapsulated for greater stability. Of course, a larger number of longitudinal sections <b>48</b> could be formed. Also the longitudinal sections <b>48</b> may themselves zigzag or may be helically arranged depending on how the openings <b>44</b> are cut into the sleeve <b>42</b>. Each different structure will possess different properties. Similarly, the circumferential sections <b>46</b> can have different forms and may be undulating. There is nothing to preclude a covering with a more complex pattern where circumferential sections and longitudinal sections are difficult to discern or are even nonexistent.
0016A second embodiment of the present invention can be seen in <figref idref="f0002">Figs. 4-6</figref>. Instead of having a "lacey" graft structure, a slitted outer sleeve is used to provide partial encapsulation of the stent, the slits providing flexibility to the structure, allowing the stent to expand and retract more readily. In <figref idref="f0002">Fig. 4</figref>, four longitudinal slits <b>52</b> run the length of the stent, leaving 5 to 10mm of uncut sleeve at the ends. The slits are formed at 0°, 90°, 180°, and 270°, and are oriented to pass over a peak portion of each zigzag ring stent <b>30</b> (<figref idref="f0002">Fig. 6). Fig. 5</figref> shows circumferential slits <b>62</b>, wherein slits are cut circumferentially around the sleeve <b>60</b> at spaced intervals, preferably to coincide with a stent ring. At each radial section, two slits are cut around the circumference at evenly spaced intervals. In a first radial section, the slits span from 0° to 90° and from 180° to 270°. Each successive radial section has a pair of slits which are offset 90° from the previous pair. Thus, a second radial section will have slits spanning from 90° to 180° and from 270° to 0°. Beside the configurations shown in <figref idref="f0002">Figs. 4 and 5</figref>, a number of other slit configurations are possible, including diagonal and sinusoidal as will be appreciated by one skilled in the art. As shown in <figref idref="f0002">Fig. 6</figref>, a sleeve <b>70</b> is placed over the ring stents <b>30</b> and the underlying tubular graft <b>20</b> to form a new structure <b>80</b>. The longitudinal slits <b>72</b>, which are cut into sleeve <b>70</b>, differ from the slits <b>52</b> shown in <figref idref="f0002">Fig. 4</figref> in that they do not span the length of the structure <b>80</b> and are staggered around the circumference of the sleeve <b>70</b>. Ideally, the slits are aligned over the peaks in the zigzag ring stents <b>30</b>. Once the slits <b>72</b> are cut into the sleeve <b>70</b> using any of the known methods, the structure <b>80</b> is exposed to heat and pressure, such as that caused by wrapping with PTFE tape and heating in an oven, thereby causing the ePTFE regions of the slitted graft <b>70</b> to fuse or laminate to the tubular graft <b>20</b>. The slits <b>72</b> in the slitted outer sleeve <b>70</b> can be formed by using a CO<sub>2</sub> laser, razor blade or any other suitable technique known in the art. The slits enhance the flexibility of the encapsulated structure and allow radial expansion without tearing of the ePTFE. In addition, a plurality of slits help the expanded graft to grip onto the vessel wall. This is particularly important where an encapsulated stent graft is spanning a region of damaged or weakened vessel as in an aneurysm. Further, during the healing process tissues readily grow into the slits further anchoring the graft to the vessel wall.
0017An advantage that cutting slits into an ePTFE sleeve offers is that it is somewhat easier to manufacture than is the "lacey" graft. Because no material is removed the sleeve is somewhat stronger than a "lacey graft". There are a multitude of configurations possible, including cutting the slits in asymmetric fashion to achieve desired results, such as using radial, longitudinal and diagonal cuts simultaneously. Moreover, a greater number of slits can be cut into a region of the structure in which greater expansion is desired.
0018Although the above examples are described with the "lacey" and slitted grafts being placed over a stent which is itself placed over a tubular graft, this orientation can be readily reversed. That is, the "lacey" or slitted grafts can be placed on a mandrel; a stent or stents can be then placed over the "lacey" or slitted grafts, and a tubular graft can be then placed over the stent or stents. This results in a structure wherein part or much of the luminal surface is provided by the outer graft, resulting in superior healing as only a single layer of ePTFE would separate body tissues from the blood. Similarly, a structure with two "lacey" or slitted grafts is possible. By keeping the openings in one graft out of phase with those in the other graft a blood tight structure results. Nevertheless, a majority of the final surface area of the device would comprise a single layer separating body tissue from the circulating blood. Only the area actually occupied by the stent(s) and by overlap between the two grafts would present a barrier to cellular infiltration. Further such a structure would have a smaller profile when compressed because the overall amount of PTFE is reduced. Likewise, a combination of the "lacey" graft and slitted graft could be employed.
0019Zigzag stent rings have been illustrated, but it should be apparent that the inventive concepts described above would be equally applicable to sinusoidal and other stent designs. The described embodiments are to be considered illustrative rather than restrictive. The invention is further defined by the following claims.
Contents3
2 sheets
Sheet 1 Sheet 2
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| WO0071057A1 | Cites | World Intellectual Property Organization (WIPO) | Opposition |
| EP0893108A2 | Cites | European Patent Office (EPO) | Opposition |
| US4776337A | Cites | United States of America | Opposition |
| US5123917A | Cites | United States of America | Opposition |
| US60118269B | Cites | United States of America | Opposition |
| EP0893108A2 | Cites | European Patent Office (EPO) | – |
| WO9628115A | Cites | World Intellectual Property Organization (WIPO) | – |
| WO9838947A | Cites | World Intellectual Property Organization (WIPO) | – |
| WO0071057A1 | Cites | World Intellectual Property Organization (WIPO) | – |
| US60118269 | Cites | United States of America | – |
| US4776337A | Cites | United States of America | – |
| US5123917A | Cites | United States of America | – |
176 members in 13 offices
Priority claims5
| Document | Office | Kind | Date |
|---|---|---|---|
| 118269P | United States of America | – | |
| 11826999 | United States of America | P | |
| 388496 | United States of America | – | |
| 38849699 | United States of America | A | |
| 0002884 | United States of America | W |
Members176
| Document | Office | Kind | |
|---|---|---|---|
| IL116235D0 | Israel | D0 | |
| CA2215027A1 | Canada | A1 | |
| CA2566929A1 | Canada | A1 | |
| WO9628115A1 | World Intellectual Property Organization (WIPO) | A1 | |
| ZA9510700B | South Africa | B | |
| WO9721401A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU4601796A | Australia | A | |
| AR001543A1 | Argentina | A1 | |
| EP0814729A1 | European Patent Office (EPO) | A1 | |
| US5749880A | United States of America | A | |
| CA2279974A1 | Canada | A1 | |
| CA2565930A1 | Canada | A1 | |
| WO9833453A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU6149398A | Australia | A | |
| WO9833453A3 | World Intellectual Property Organization (WIPO) | A3 | |
| JPH10510196A | Japan | A | |
| EP0868154A1 | European Patent Office (EPO) | A1 | |
| WO9932051A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU8298598A | Australia | A | |
| CA2318829A1 | Canada | A1 | |
| WO9938455A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU7175998A | Australia | A | |
| US6004348A | United States of America | A | |
| JP2000501961A | Japan | A | |
| US6039755A | United States of America | A | |
| US6053943A | United States of America | A | |
| EP1003440A2 | European Patent Office (EPO) | A2 | |
| EP0814729B1 | European Patent Office (EPO) | B1 | |
| CA2361067A1 | Canada | A1 | |
| CA2361244A1 | Canada | A1 | |
| CA2371964A1 | Canada | A1 | |
| WO0045741A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO0045742A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO0045743A1 | World Intellectual Property Organization (WIPO) | A1 | |
| DE69518337D1 | Germany | D1 | |
| US6124523A | United States of America | A | |
| EP1041941A1 | European Patent Office (EPO) | A1 | |
| WO0045743B1 | World Intellectual Property Organization (WIPO) | B1 | |
| EP1054646A1 | European Patent Office (EPO) | A1 | |
| ES2151082T3 | Spain | T3 | |
| DE69518337T2 | Germany | T2 | |
| AU733860B2 | Australia | B2 | |
| US6264684B1 | United States of America | B1 | |
| JP2001510367A | Japan | A | |
| US2001020181A1 | United States of America | A1 | |
| US2001021870A1 | United States of America | A1 | |
| US2001025131A1 | United States of America | A1 | |
| US2001032009A1 | United States of America | A1 | |
| EP1148841A1 | European Patent Office (EPO) | A1 | |
| EP1148842A1 | European Patent Office (EPO) | A1 | |
| EP1148843A1 | European Patent Office (EPO) | A1 | |
| WO0045742A9 | World Intellectual Property Organization (WIPO) | A9 | |
| US2001039446A1 | United States of America | A1 | |
| JP2001526080A | Japan | A | |
| JP2002501779A | Japan | A | |
| US2002038143A1 | United States of America | A1 | |
| US6383214B1 | United States of America | B1 | |
| US6398803B1 | United States of America | B1 | |
| MXPA01007789A | Mexico | A | |
| MXPA01007790A | Mexico | A | |
| US6451047B2 | United States of America | B2 | |
| JP2002536055A | Japan | A | |
| JP2002536056A | Japan | A | |
| JP2002536057A | Japan | A | |
| US2003006528A1 | United States of America | A1 | |
| EP1148843B1 | European Patent Office (EPO) | B1 | |
| US6558414B2 | United States of America | B2 | |
| AT237287T | Austria | T | |
| ATE237287T1 | Austria | T1 | |
| DE60002161D1 | Germany | D1 | |
| US6579314B1 | United States of America | B1 | |
| MXPA01007785A | Mexico | A | |
| EP0868154B1 | European Patent Office (EPO) | B1 | |
| US2003191519A1 | United States of America | A1 | |
| US2003201058A1 | United States of America | A1 | |
| DE69531872D1 | Germany | D1 | |
| DE60002161T2 | Germany | T2 | |
| ES2195883T3 | Spain | T3 | |
| EP1380270A2 | European Patent Office (EPO) | A2 | |
| JP3507503B2 | Japan | B2 | |
| EP1380270A3 | European Patent Office (EPO) | A3 | |
| US6740115B2 | United States of America | B2 | |
| ES2208700T3 | Spain | T3 | |
| US6758858B2 | United States of America | B2 | |
| DE69531872T2 | Germany | T2 | |
| US6770087B2 | United States of America | B2 | |
| US6790226B2 | United States of America | B2 | |
| US6797217B2 | United States of America | B2 | |
| US2004204757A1 | United States of America | A1 | |
| US2004232588A1 | United States of America | A1 | |
| US2004236400A1 | United States of America | A1 | |
| US2004236402A1 | United States of America | A1 | |
| EP1003440B1 | European Patent Office (EPO) | B1 | |
| DE69829754D1 | Germany | D1 | |
| CA2361067C | Canada | C | |
| EP1148842B1 | European Patent Office (EPO) | B1 | |
| AT298545T | Austria | T | |
| ATE298545T1 | Austria | T1 | |
| EP1557258A2 | European Patent Office (EPO) | A2 | |
| DE60021061D1 | Germany | D1 |
80 legal events, as 7 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Notification of lapseLapsedST | ST | FR | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119 | R119 | DE | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Epo decision maintaining patent in amended form now finalR102 | R102 | DE | |
| Patent maintained in amended form27A | 27A | EP | |
| Designated contracting statesAK | AK | EP | |
| Patent maintained in amended formORIGINAL CODE: 0009272PUAH | PUAH | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: PATENT MAINTAINED AS AMENDEDSTAA | STAA | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Information provided on ipc code assigned after grantRIC2 | RIC2 | EP | |
| Information provided on ipc code assigned after grantRIC2 | RIC2 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Reply to examination report in opposition receivedOppositionORIGINAL CODE: EPIDOSNORE3PLBC | PLBC | EP | |
| Examination report in opposition despatched + time limitOppositionORIGINAL CODE: EPIDOSNORE2PLAY | PLAY | EP | |
| Appeal procedure closedAppealORIGINAL CODE: EPIDOSNNOA9OAPBU | APBU | EP | |
| Date of receipt of statement of grounds of appeal recordedAppealORIGINAL CODE: EPIDOSNNOA3OAPBQ | APBQ | EP | |
| Opposition filed (corrected)OppositionR26 | R26 | EP | |
| Date of receipt of notice of appeal recordedAppealORIGINAL CODE: EPIDOSNNOA2OAPBP | APBP | EP | |
| Opposition data, opponent's data or that of the opponent's representative modifiedOppositionORIGINAL CODE: 0009299OPPOPLAB | PLAB | EP | |
| Appeal reference modifiedAppealORIGINAL CODE: EPIDOSCREFNOAPAH | APAH | EP | |
| Date of receipt of notice of appeal recordedAppealORIGINAL CODE: EPIDOSNNOA2OAPBP | APBP | EP | |
| Patent lapsedLapsedMM4A | MM4A | IE | |
| Opposition filed (corrected)OppositionR26 | R26 | EP | |
| Party data changed (patent owner data changed or rights of a patent transferred)RAP2 | RAP2 | EP | |
| Opposition data, opponent's data or that of the opponent's representative modifiedOppositionORIGINAL CODE: 0009299OPPOPLAB | PLAB | EP | |
| Examination of admissibility of opposition: information related to despatch of communication + time limit deletedOppositionORIGINAL CODE: EPIDOSDOPE2PLAQ | PLAQ | EP | |
| Examination of admissibility of opposition: information related to receipt of reply deletedOppositionORIGINAL CODE: EPIDOSDOPE4PLAR | PLAR | EP | |
| Unpublished change to opponent dataORIGINAL CODE: EPIDOS OPPOPLBQ | PLBQ | EP | |
| Opposition filed (corrected)OppositionR26 | R26 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Opposition data, opponent's data or that of the opponent's representative modifiedOppositionORIGINAL CODE: 0009299OPPOPLAB | PLAB | EP | |
| Examination of admissibility of opposition: information related to despatch of communication + time limit deletedOppositionORIGINAL CODE: EPIDOSDOPE2PLAQ | PLAQ | EP | |
| Examination of admissibility of opposition: information related to receipt of reply deletedOppositionORIGINAL CODE: EPIDOSDOPE4PLAR | PLAR | EP | |
| Unpublished change to opponent dataORIGINAL CODE: EPIDOS OPPOPLBQ | PLBQ | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Change of name or company nameCD | CD | FR | |
| Reply of patent proprietor to notice(s) of opposition receivedOppositionORIGINAL CODE: EPIDOSNOBS3PLBB | PLBB | EP | |
| Notice of opposition and request to file observation + time limit sentOppositionORIGINAL CODE: EPIDOSNOBS2PLAX | PLAX | EP | |
| Opposition filedOpposition26 | 26 | EP | |
| Notice of opposition and request to file observation + time limit sentOppositionORIGINAL CODE: EPIDOSNOBS2PLAX | PLAX | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Opposition filedOppositionORIGINAL CODE: 0009260PLBI | PLBI | EP | |
| Unpublished change to opponent dataORIGINAL CODE: EPIDOS OPPOPLBQ | PLBQ | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Patent ceasedCeasedPL | PL | CH | |
| Fr: translation filedET | ET | EP | |
| Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents actLapsedNLV1 | NLV1 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| Corresponds to:REF | REF | EP | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOS IGRAGRAH | GRAH | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOS IGRAGRAH | GRAH | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1148843
- Application
- 9157454
Titles3
- German
- TEILEINKAPSELUNG VON STENTS
- English
- PARTIAL ENCAPSULATION OF STENTS
- French
- ENCAPSULATION PARTIELLE D'ENDOPROTHESES
Classification
- CPC, 10
- A61F2/07
- A61F2/915
- A61F2002/072
- A61F2250/0029
- Y10S623/901
- A61F2/89
- Y10T156/1062
- Y10T156/109
- Y10T156/1026
- Y10T156/1056
- IPC, 4
- A61F2 06
- A61F2 07
- A61F2 00
- A61F2 04
Designated states19
- Contracting states, 19
- Austria
- Belgium
- Switzerland
- Cyprus
- Germany
- Denmark
- Spain
- Finland
- France
- United Kingdom
- Greece
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Sweden